Results 161 to 170 of about 573,768 (206)

Pharmacology and Clinical Pharmacology of Vigabatrin [PDF]

open access: possibleJournal of Child Neurology, 1991
Vigabatrin is an enzyme-activated, irreversible inhibitor of γ-aminobutyric acid (GABA) aminotransferase, which causes a marked increase in cerebral GABA concentration and a resulting anticonvulsant action. Recovery from its effects requires the synthesis of new enzyme, and this may take several days following a single dose.
openaire   +2 more sources

Pharmacology

International Anesthesiology Clinics, 1999
When performing IVCS, one must never forget the primary goal of providing patient comfort without compromising cardiopulmonary function or the patient's ability to react purposely to verbal commands and physical stimuli. When it is anticipated that required sedation will lead to loss of protective airway reflexes, such patients require a greater level ...
K P, Lewis, G D, Stanley
openaire   +2 more sources

Clinical Pharmacology

JAMA: The Journal of the American Medical Association, 1989
The issue of what drug effects to measure, surrogate end points, has been emphasized by two recent clinical trials. Several recent studies have given us new information about why different people react so differently to the same dose of the same medicine.
openaire   +5 more sources

CFTR pharmacology [PDF]

open access: possibleCellular and Molecular Life Sciences, 2016
CFTR protein is an ion channel regulated by cAMP-dependent phosphorylation and expressed in many types of epithelial cells. CFTR-mediated chloride and bicarbonate secretion play an important role in the respiratory and gastrointestinal systems. Pharmacological modulators of CFTR represent promising drugs for a variety of diseases.
Zegarra-Moran, Olga   +1 more
openaire   +3 more sources

Pharmacology

The Journal of Cardiovascular Nursing, 1998
Inadequate pain relief has been identified as a common problem after coronary artery bypass surgery, Understanding the pharmacology of analgesics commonly used after cardiovascular surgery is a fundamental part of effective pain management. The pharmacologic properties for two analgesic drug classes, opioid and nonopioid, are reviewed.
openaire   +2 more sources

PHARMACOLOGY OF PYRAZOLOPYRIDINES

Clinical Neuropharmacology, 1984
Pyrazolopyridines (PZP's) in general represent a chemically unique class of non-sedative anxiolytic agents. Tracazolate (ICI 136,753) is a member of pyrazolopyridine series that has shown anxiolytic properties in animal models. Tracazolate demonstrates a wider separation between sedative and therapeutic doses than do benzodiazepines.
Andre I. Salama   +3 more
openaire   +4 more sources

Pharmacology of Ifosfamide

Oncology, 2003
Ifosfamide is a bifunctional alkylating agent, used as a racemic mixture by intravenous route in the treatment of various tumors. It is an oxazaphosphorine derivative with a structural formula similar to that of cyclophosphamide. As a prodrug it requires activation in the liver by a cytochrome mixed-function oxidase system.
FRANCESCHI, Loretta, FURLANUT, Mario
openaire   +4 more sources

PHARMACOLOGY OF NEBIVOLOL

Pharmacological Research, 1998
Nebivolol is a new selective beta 1-adrenergic blocking agent, that possesses a peculiar pharmacodynamic profile and an original chemical structure, by which it differs from traditional beta 1-blockers. Nebivolol is a racemic mixture of two enantiomers in equal ratios. It is endowed with a highly selective beta 1-blocking activity, and does not show an
MANGRELLA M   +3 more
openaire   +4 more sources

Pharmacology of Migraine

Annual Review of Pharmacology and Toxicology, 1981
Stabilization of serotonergic neurotransmission by depressing the activity of serotonergic neurons may be the common mode of action of drugs effective in migraine. By serotonin receptor agonism, by prolonging the biologic half-life of serotonin in the synaptic cleft (through blockade of its re-uptake or metabolic degradation), by an increase in its ...
openaire   +5 more sources

Radiotheranostics in oncology: Making precision medicine possible

Ca-A Cancer Journal for Clinicians, 2023
Eric O Aboagye
exaly  

Home - About - Disclaimer - Privacy